Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.

Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.

View in: PubMed

subject areas

Acute Kidney Injury
Adenine Nucleotides
Adult
Age Factors
Aged
Alemtuzumab
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Arabinonucleosides
Female
Glomerular Filtration Rate
Hematologic Neoplasms
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute
Lymphoma, Non-Hodgkin
Male
Melphalan
Middle Aged
Recurrence
Risk
Survival Analysis
Transplantation Conditioning
Transplantation, Homologous

authors with profiles

Olatoyosi Odenike
Peter O'Donnell
Justin Kline
Wendy Stock
Lucy Godley
Richard A. Larson
Koen Van Besien